Inventor
HIROKI SASAKI
Inventor
JP
Overview
Patents· 6 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes13%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations13%
C07KPeptides13%
C12NMicroorganisms or enzymes13%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture9%
H04NPictorial communication, e.g. television9%
B65HHandling thin or filamentary material, e.g. sheets, webs, cables4%
G02BOptical elements, systems or apparatus4%
G03BApparatus or arrangements for taking photographs or for projecting or viewing them4%
G03GElectrography4%
PatentTitleYear
12,304,951Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody202512,253,818Image forming apparatus202512,227,586Anti-CLDN4/anti-CD137 bispecific antibody202512,154,920Camera module having curved imager202411,897,954Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody202411,736,830Solid-state imaging element2023Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2023–2024Patents assigned to DENSO CORP (2)· patent assignee history
2023Patents assigned to MIRISE Technologies Corporation (1)· patent assignee history
2023–2025Based in JP· patent location history
2024–2025Patents assigned to ASTELLAS PHARMA INC (3)· patent assignee history
2024–2025Patents assigned to NAT CANCER CT (3)· patent assignee history
2025Patents assigned to CANON KK (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ASTELLAS PHARMA INC | 3 | 2024–2025 |
| NAT CANCER CT | 3 | 2024–2025 |
| DENSO CORP | 2 | 2023–2024 |
| CANON KK | 1 | 2025 |
| MIRISE Technologies Corporation | 1 | 2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| JP | 6 | 2023–2025 |